{"title":"摘要:TAM受体在胰腺癌肿瘤和间质室中的不同作用","authors":"Nancy P. Kren, Alisha Holtzhausen, Doug Graham, Shelton Earp, Yuliya Pylayeva Gupta","doi":"10.1158/1538-7445.pancreatic25-a083","DOIUrl":null,"url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options, poor prognosis, and a profoundly immunosuppressive tumor microenvironment (TME). The TAM family of receptor tyrosine kinases—Tyro3, Axl, and MerTK—are known for their roles in maintaining immune homeostasis by promoting the clearance of apoptotic cells in a non-inflammatory manner, thus preventing chronic inflammation and autoimmunity. However, their individual roles in shaping immune tolerance within the TME, especially in the context of cancer, remain unclear and may differ from their tumor-intrinsic functions, where they are often overexpressed. To dissect the host (stromal) contributions of TAM receptors in PDAC, we utilized syngeneic mouse models with targeted deletion of Tyro3 or Axl (tyro3-/- and axl-/- mice). Loss of Tyro3 in the tumor stroma, particularly in myeloid cells, significantly impaired tumor growth and was associated with enhanced type I interferon signaling and upregulation of antigen presentation pathways. In contrast, stromal deletion ofAxl modestly promoted tumor growth and failed to reverse the immunosuppressive TME, as shown by gene expression and flow cytometry analyses. When assessing metastatic potential using a splenic injection model of KPC tumor cells, liver metastases were significantly reduced in tyro3-/- mice. Conversely, stromal loss of Axl led to a marked increase in metastatic outgrowth. Since Axl is known to drive tumor cell proliferation, invasion - and is upregulated in tumor cells resistant to KRAS inhibition - we further explored its role in tumor-intrinsic versus stromal contexts. Axl knockdown in tumor cells alone had no effect on primary tumor growth but completely reversed the increased metastatic phenotype observed in Axl-deficient stroma. These findings reveal distinct and even opposing roles for Tyro3 and Axl within the host immune compartment in PDAC. While Tyro3 promotes immune evasion and tumor progression, Axl’s tumor-intrinsic expression plays a dominant role in driving metastasis. Based on these insights, we are currently testing whether co-targeting Axl and KRAS with small-molecule inhibitors could produce synergistic anti-tumor effects that outweigh potentially adverse TME consequences. Collectively, our data underscores the need to consider the unique, context-dependent roles of individual TAM receptors rather than assuming functional redundancy across the family. Citation Format: Nancy P. Kren, Alisha Holtzhausen, Doug Graham, Shelton Earp, Yuliya Pylayeva Gupta. Divergent Roles of TAM Receptors in Tumor and Stromal Compartments of Pancreatic Cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3): nr A083.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"51 1","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract A083: Divergent Roles of TAM Receptors in Tumor and Stromal Compartments of Pancreatic Cancer\",\"authors\":\"Nancy P. Kren, Alisha Holtzhausen, Doug Graham, Shelton Earp, Yuliya Pylayeva Gupta\",\"doi\":\"10.1158/1538-7445.pancreatic25-a083\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options, poor prognosis, and a profoundly immunosuppressive tumor microenvironment (TME). The TAM family of receptor tyrosine kinases—Tyro3, Axl, and MerTK—are known for their roles in maintaining immune homeostasis by promoting the clearance of apoptotic cells in a non-inflammatory manner, thus preventing chronic inflammation and autoimmunity. However, their individual roles in shaping immune tolerance within the TME, especially in the context of cancer, remain unclear and may differ from their tumor-intrinsic functions, where they are often overexpressed. To dissect the host (stromal) contributions of TAM receptors in PDAC, we utilized syngeneic mouse models with targeted deletion of Tyro3 or Axl (tyro3-/- and axl-/- mice). Loss of Tyro3 in the tumor stroma, particularly in myeloid cells, significantly impaired tumor growth and was associated with enhanced type I interferon signaling and upregulation of antigen presentation pathways. In contrast, stromal deletion ofAxl modestly promoted tumor growth and failed to reverse the immunosuppressive TME, as shown by gene expression and flow cytometry analyses. When assessing metastatic potential using a splenic injection model of KPC tumor cells, liver metastases were significantly reduced in tyro3-/- mice. Conversely, stromal loss of Axl led to a marked increase in metastatic outgrowth. Since Axl is known to drive tumor cell proliferation, invasion - and is upregulated in tumor cells resistant to KRAS inhibition - we further explored its role in tumor-intrinsic versus stromal contexts. Axl knockdown in tumor cells alone had no effect on primary tumor growth but completely reversed the increased metastatic phenotype observed in Axl-deficient stroma. These findings reveal distinct and even opposing roles for Tyro3 and Axl within the host immune compartment in PDAC. While Tyro3 promotes immune evasion and tumor progression, Axl’s tumor-intrinsic expression plays a dominant role in driving metastasis. Based on these insights, we are currently testing whether co-targeting Axl and KRAS with small-molecule inhibitors could produce synergistic anti-tumor effects that outweigh potentially adverse TME consequences. Collectively, our data underscores the need to consider the unique, context-dependent roles of individual TAM receptors rather than assuming functional redundancy across the family. Citation Format: Nancy P. Kren, Alisha Holtzhausen, Doug Graham, Shelton Earp, Yuliya Pylayeva Gupta. Divergent Roles of TAM Receptors in Tumor and Stromal Compartments of Pancreatic Cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3): nr A083.\",\"PeriodicalId\":9441,\"journal\":{\"name\":\"Cancer research\",\"volume\":\"51 1\",\"pages\":\"\"},\"PeriodicalIF\":16.6000,\"publicationDate\":\"2025-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.pancreatic25-a083\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1538-7445.pancreatic25-a083","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
胰腺导管腺癌(PDAC)是一种高度侵袭性的癌症,治疗方案有限,预后差,肿瘤微环境(TME)具有深度免疫抑制作用。TAM家族的受体酪氨酸激酶- tyro3, Axl和mertk -以非炎症方式促进凋亡细胞的清除来维持免疫稳态,从而预防慢性炎症和自身免疫而闻名。然而,它们在TME中形成免疫耐受的个体作用,特别是在癌症背景下,仍然不清楚,可能与它们的肿瘤内在功能不同,在肿瘤内在功能中它们经常过度表达。为了剖析TAM受体在PDAC中的宿主(间质)贡献,我们使用了靶向缺失Tyro3或Axl的同基因小鼠模型(Tyro3 -/-和Axl -/-小鼠)。肿瘤基质中Tyro3的缺失,特别是髓细胞中Tyro3的缺失,会显著损害肿瘤生长,并与I型干扰素信号传导增强和抗原递呈途径上调相关。相比之下,基因表达和流式细胞术分析显示,基质缺失axl适度促进肿瘤生长,但未能逆转免疫抑制的TME。当使用脾注射KPC肿瘤细胞模型评估转移潜力时,tyro3-/-小鼠的肝转移明显减少。相反,基质Axl的缺失导致转移性生长的显著增加。由于已知Axl可以驱动肿瘤细胞的增殖和侵袭,并且在抗KRAS抑制的肿瘤细胞中表达上调,因此我们进一步探讨了它在肿瘤内禀和间质环境中的作用。在肿瘤细胞中单独敲除Axl对原发肿瘤生长没有影响,但完全逆转了在缺乏Axl的基质中观察到的转移表型的增加。这些发现揭示了Tyro3和Axl在PDAC宿主免疫室中的不同甚至相反的作用。Tyro3促进免疫逃避和肿瘤进展,而Axl的肿瘤内在表达在驱动转移中起主导作用。基于这些见解,我们目前正在测试小分子抑制剂共同靶向Axl和KRAS是否可以产生协同抗肿瘤作用,从而超过潜在的不良TME后果。总的来说,我们的数据强调需要考虑单个TAM受体的独特的、依赖于环境的作用,而不是假设整个家族的功能冗余。引文格式:Nancy P. Kren, Alisha Holtzhausen, Doug Graham, Shelton Earp, Yuliya Pylayeva Gupta。TAM受体在胰腺癌肿瘤和间质室中的不同作用[摘要]。摘自:AACR癌症研究特别会议论文集:胰腺癌研究进展-新兴科学驱动变革解决方案;波士顿;2025年9月28日至10月1日;波士顿,MA。费城(PA): AACR;癌症研究2025;85(18_Suppl_3): nr A083。
Abstract A083: Divergent Roles of TAM Receptors in Tumor and Stromal Compartments of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options, poor prognosis, and a profoundly immunosuppressive tumor microenvironment (TME). The TAM family of receptor tyrosine kinases—Tyro3, Axl, and MerTK—are known for their roles in maintaining immune homeostasis by promoting the clearance of apoptotic cells in a non-inflammatory manner, thus preventing chronic inflammation and autoimmunity. However, their individual roles in shaping immune tolerance within the TME, especially in the context of cancer, remain unclear and may differ from their tumor-intrinsic functions, where they are often overexpressed. To dissect the host (stromal) contributions of TAM receptors in PDAC, we utilized syngeneic mouse models with targeted deletion of Tyro3 or Axl (tyro3-/- and axl-/- mice). Loss of Tyro3 in the tumor stroma, particularly in myeloid cells, significantly impaired tumor growth and was associated with enhanced type I interferon signaling and upregulation of antigen presentation pathways. In contrast, stromal deletion ofAxl modestly promoted tumor growth and failed to reverse the immunosuppressive TME, as shown by gene expression and flow cytometry analyses. When assessing metastatic potential using a splenic injection model of KPC tumor cells, liver metastases were significantly reduced in tyro3-/- mice. Conversely, stromal loss of Axl led to a marked increase in metastatic outgrowth. Since Axl is known to drive tumor cell proliferation, invasion - and is upregulated in tumor cells resistant to KRAS inhibition - we further explored its role in tumor-intrinsic versus stromal contexts. Axl knockdown in tumor cells alone had no effect on primary tumor growth but completely reversed the increased metastatic phenotype observed in Axl-deficient stroma. These findings reveal distinct and even opposing roles for Tyro3 and Axl within the host immune compartment in PDAC. While Tyro3 promotes immune evasion and tumor progression, Axl’s tumor-intrinsic expression plays a dominant role in driving metastasis. Based on these insights, we are currently testing whether co-targeting Axl and KRAS with small-molecule inhibitors could produce synergistic anti-tumor effects that outweigh potentially adverse TME consequences. Collectively, our data underscores the need to consider the unique, context-dependent roles of individual TAM receptors rather than assuming functional redundancy across the family. Citation Format: Nancy P. Kren, Alisha Holtzhausen, Doug Graham, Shelton Earp, Yuliya Pylayeva Gupta. Divergent Roles of TAM Receptors in Tumor and Stromal Compartments of Pancreatic Cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3): nr A083.
期刊介绍:
Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research.
With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445.
Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.